Clinical trial
Canakinumab for Treatment of Adult-onset Still's Disease
NCT02204293 · Charite University, Berlin, Germany, Other · Terminated
Key facts
| NCT number | NCT02204293 |
|---|---|
| Title | Canakinumab for Treatment of Adult-onset Still's Disease |
| Official title | Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension |
| Acronym | CONSIDER |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult-Onset Still´s Disease |
| Intervention type | Drug |
| Interventions | Canakinumab, Placebo |
| Enrollment | 36 |
| Start date | Jun 21, 2012 |
| Primary completion | May 5, 2018 |
| Completion | May 5, 2018 |
| First posted | Jul 30, 2014 |
| Last update posted | Aug 7, 2020 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: